Xenon Pharmaceuticals (XENE) Wells Fargo 21st Annual Healthcare Conference summary

Company overview and strategic direction

• Transitioning from ion channel drug discovery to commercial stage, with lead asset azetukalner nearing NDA filing for focal onset seizures in the U.S.

• Expanding azetukalner into neuropsychiatry and advancing early-stage pipeline assets in pain and epilepsy, including a Nav1.7 inhibitor and another Kv7 mechanism drug, both in phase I.

• Targeting full integration as a biopharma company by late 2027, supported by a robust and diversified pipeline.

Clinical development and conference highlights

• Presented six posters and an oral encore of phase III X-TOLE2 data at the European Epilepsy Congress, receiving positive feedback from key opinion leaders.

• Highlighted azetukalner's novel Kv7 mechanism, ease of use, and synergy with other anti-seizure medications, addressing unmet needs in focal onset seizures.

• Emphasized the benefit of no required titration and strong efficacy across multiple doses, reducing patient anxiety about breakthrough seizures.

Regulatory and label strategy

• NDA filing for azetukalner in focal onset seizures is imminent, aiming for a broad label with four efficacious doses (10, 15, 20, 25 mg).

• Strong efficacy and safety data support inclusion of all doses, allowing clinicians flexibility based on patient BMI and seizure severity.

• Commercial strategy includes flat pricing across doses to maximize physician choice without economic impact.